Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Archives

Lexicon, BridgeBio, Esperion, Pfizer, More Celebrate Wins at 71st ACC Meeting

AstraZeneca, BioSpace, Cholesterol, Clinical Data, Clinical Trial Endpoints, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), Heart Attacks, Heart Failure with Reduced Ejection Fraction (HFrEF), Pfizer, Primary Endpoints, R&D, Regeneron Pharmaceuticals, Sanofi, Small-Interfering RNA (siRNA) Class, Strokes, TTR Amyloidosis (ATTR)

The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.

April 4, 2022/by BioSpace

New Inclisiran Analysis Evaluated LDL-C Reduction Across Individual Patient

Analysis, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Trials, Data, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), European Medicines Agency (EMA), European Society of Cardiology (ESC) Congress, FDA, Hyperlipidemia, Placebo, Post-Hoc Analysis, Primary Hyperlipidemia, R&D, Small-Interfering RNA (siRNA) Class

Novartis announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a first-in-class investigational treatment for hyperlipidemia in adults.

August 30, 2020/by Andrew Humphreys